- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05845983
LA Improves the Prognosis of Patients With ICVD
Lactobacillus Acidophilus Improves the Prognosis (Cognitive Function) of Patients With Ischemic Cerebrovascular Disease After Surgery: a Multicenter, Prospective, Three-blind, Placebo-randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ischemic cerebrovascular disease, as a common form of stroke, is one of the main causes of global morbidity and mortality. The mortality rate of this disease is relatively high, and the treatment prognosis is poor, which will cause serious harm to the life and safety of patients. The optimal treatment for ischemic cerebrovascular disease is still unclear, and the effects of different treatments are still controversial. Therefore, it is of great clinical significance to explore a safe and simple adjuvant treatment method to help patients recover their nervous system function faster and better.
At present, numerous clinical trials have demonstrated that probiotics can improve cognitive function in people under multimodal. Adding intestinal probiotics can improve the intestinal flora distribution, and significantly improve cognitive function in elderly patients with mild cognitive impairment and prevention of brain atrophy. Lactobacillus acidophilus is rich in short chain fatty acids (SCFA). Clinical studies have shown that SCFA levels are negatively correlated with the severity and prognosis of ischemic stroke. Numerous studies have demonstrated that the intestinal supply short chain fatty acids can improve cognitive function, in the middle cerebral artery occlusion (MCAO) induced by acute cerebral ischemia model, rich in the intestines of SCFA can cure acute cerebral ischemia in mice induced by nerve injury. More importantly, in mice with acute cerebral ischemia induced by middle cerebral artery occlusion (MCAO) and chronic cerebral ischemia caused by bilateral common carotid artery stenosis (BCAS), we have previously found that mice have cognitive impairment, accompanied by intestinal flora dysregulation.
Lactobacillus acidophilus administration has a significant effect on improving cognitive function. Based on the above research background and the basis of previous studies, the researchers believe that the administration of Lactobacillus acidophilus solid drink (pure Lactobacillus acidophilus strain) can improve the cognitive function of patients with cerebral ischemia through the "brain-gut axis", and increase the reliability and scope of revascularization, and ultimately improve the prognosis of patients with ischemic cerebrovascular disease.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Huaqiu Zhang, PhD
- Phone Number: +8613419632963
- Email: lyc@tjh.tjmu.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Between 35 and 65 years old;
- Han nationality;
- Diagnosed as ischemic cerebrovascular disease with mild to moderate symptoms;
- Can communicate normally, complete neuropsychological tests independently, and sign informed consent;
- No previous surgical history;
- No contraindications such as PET, MRI and DSA;
- No history of stroke identified by imaging;
- No family history of other chronic diseases, cancer, mental illness or dementia;
- Improved Rankin scale score ≤2;
- Ischemic symptoms appeared in the carotid area ≤3 months before the visit;
- In line with the surgical treatment of ischemic cerebrovascular disease;
Exclusion Criteria:
- previous dementia;
- hearing or visual impairment;
- Drugs that may or are known to influence cognitive abuse;
- alcohol addiction;
- Diagnosis of depression, schizophrenia and other psychiatric diseases;
- MRI showed severe cerebral infarction;
- Those allergic to Lactobacillus acidophilus;
- Baseline CT showed intracranial hemorrhage;
- ischemic onset accompanied by epilepsy;
- illiteracy;
- pregnancy or breastfeeding;
- any serious medical condition that may interact with treatment;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LA treatment group
The patient received conventional treatment and Lactobacillus acidophilus treatment for three months after surgery.
|
Lactobacillus acidophilus solid drink (pure bacteria, food grade, JYLA-191, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g (containing 2*10^10CFU), twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
|
Placebo Comparator: Control group
The patient received conventional treatment and Maltodextrin treatment (placebo) for three months after surgery.
|
Maltodextrin solid drink (food grade, MD20, Shandong Zhongke Jia-yi Biological Engineering Co., LTD.), 3g, twice a day, once in the morning and once in the evening, 1 bag each time, by drinking water, direct oral intake, 1 month/course, continuous use for three courses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mini-mental State Examination (MMSE, 0-30) scale
Time Frame: Three months.
|
Higher scale scores mean better cognitive function.
|
Three months.
|
Montreal Cognitive Assessment (MoCA, 0-30) scale
Time Frame: Three months.
|
Higher scale scores mean better cognitive function.
|
Three months.
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJ-IRB20230304
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemia
-
Beytepe Murat Erdi Eker State HospitalCompletedAnterior Segment Ischemia (Diagnosis)
-
University Hospital, Strasbourg, FranceTerminatedVascular Surgery | Ischemia-reperfusion | Ischemia PreconditioningFrance
-
University Hospital, Strasbourg, FranceCompletedSkeletal Muscle Ischemia | Severe Lower Limb Ischemia | Mitochondrial DysfunctionFrance
-
Egyptian Cerebro-Cardio-Vascular AssociationUnknownRisk Factor, Cardiovascular | Ischemia, Myocardial | Ischemia, Cerebral
-
Technische Universität DresdenRecruitingRetinal IschemiaGermany
-
Centre Hospitalier Universitaire de NiceCompleted
-
Attikon HospitalUniversity Hospital of PatrasCompleted
-
Beth Israel Deaconess Medical CenterWithdrawn
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Hospices Civils de LyonCompleted
Clinical Trials on Maltodextrin
-
Northwestern UniversityUniversity of Illinois at ChicagoActive, not recruitingParkinson Disease | Dietary Modification | Intestinal Bacteria Flora DisturbanceUnited States
-
University of BathUniversity of BirminghamCompleted
-
NestléCompleted
-
University of FoggiaCasa Sollievo della Sofferenza IRCCSActive, not recruitingCesarean Section ComplicationsItaly
-
RDC Clinical Pty LtdNot yet recruitingJoint Pain | Muscle Pain | Chronic Inflammation | MobilityAustralia
-
Columbia UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIV | Breast Feeding | Infant MorbiditySouth Africa
-
Biofortis, Merieux NutriSciencesLonza Inc.CompletedGut MicrobiotaUnited States
-
SyralBiofortis Mérieux NutriSciences; CreaBio Rhone-AlpesCompletedHealthy | Functional ConstipationFrance
-
Nanjing PLA General HospitalCompletedIrritable Bowel Syndrome
-
NestléCompletedSeasonal Allergic RhinitisSwitzerland